Stephanie E. Chiuve

ORCID: 0000-0002-3524-8917 · 13 papers in corpus
observational 2022
BMJ open ·doi:10.1136/bmjopen-2021-052765

OBJECTIVES: To examine women's perceptions of endometriosis-associated disease burden and its impact on life decisions and goal attainment. DESIGN: An anonymous online survey was distributed in October 2018 through the social media network…

other 2022
British journal of clinical pharmacology ·doi:10.1111/bcp.15440

AIM: Elagolix, a gonadotropin-releasing hormone receptor antagonist, was recently approved for heavy menstrual bleeding associated with uterine fibroids (UF, Oriahnn) at a dose of 300 mg twice daily (BID) in combination with add-back therap…

observational 2022
Journal of Epidemiology and Community Health ·doi:10.1136/jech-2020-214565

BACKGROUND: Depression and anxiety are prevalent among women with uterine fibroids (UF). The rate of mental health diagnoses in women with UF has not been studied. METHODS: Women aged 18-50 years with diagnosed UF were identified in the Op…

observational 2021
Pharmacoepidemiology and drug safety ·doi:10.1002/pds.5209

BACKGROUND: Women with endometriosis are prescribed opioids for pain relief but may be vulnerable to chronic opioid use given their comorbidity profile. METHODS: A cohort study was conducted in the Clinformatics™ DataMart database between …

other 2021
Clinical and translational science ·doi:10.1111/cts.13006

Decline of bone mineral density (BMD) during menopause is related to increased risk of fractures in postmenopausal women, however, this relationship in premenopausal women has not been established. To quantify this relationship, real-world …

observational 2021
Pharmacoepidemiology and drug safety ·doi:10.1002/pds.5333

BACKGROUND: The prevalence of adenomyosis is underestimated due to lack of a specific diagnostic code and diagnostic delays given most diagnoses occur at hysterectomy. OBJECTIVES: To identify women with adenomyosis using indicators derived…

2020
·doi:10.1002/jbm4.10401/v2/response1
observational 2020
American Journal of Epidemiology ·doi:10.1093/aje/kwaa249

The purpose of this study was to compare the incidence of mental health outcomes in women in the United States with and without documented endometriosis. In a retrospective matched-cohort study using administrative health claims data from O…

other 2020
JBMR plus ·doi:10.1002/jbm4.10401

Elagolix, a gonadotrophin-releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long-term effects of BMD loss later in life cannot be directly assessed and has n…

2020
·doi:10.1016/j.fertnstert.2020.08.587
observational 2019
·doi:10.1097/01.aog.0000558834.25763.06

INTRODUCTION: Women with endometriosis are prescribed opioids for pain relief but may have other risk factors for chronic opioid use. The identification of predictors of chronic use in this population may provide clinical guidance for treat…

observational 2019
·doi:10.1097/01.aog.0000559289.36694.14

INTRODUCTION: Women with endometriosis may be prescribed opioids for management of endometriosis-related pain symptoms or in the context of surgical procedures. Once exposed, these women may be vulnerable to chronic opioid use given their c…

2018
·doi:10.1016/j.fertnstert.2018.07.1076